Tetragon Biosciences

Tetragon Biosciences is a Seattle-based biotechnology company specializing in the creation of de novo protein therapeutics through advanced computational design. A spin-out from the University of Washington’s Institute for Protein Design, the company utilizes AI and Rosetta-based tools to engineer hyper-stable miniproteins with high affinity for specific disease targets. Their primary focus is on infectious diseases, with lead programs targeting respiratory viruses like SARS-CoV-2 and influenza. These synthetic proteins are designed to be more potent, easier to manufacture, and more resistant to viral escape than traditional monoclonal antibodies. Tetragon's platform aims to provide a rapid response capability for emerging pandemic threats and seasonal viral mutations. The company represents a new generation of "digital-to-biological" drug discovery firms leveraging the latest breakthroughs in protein folding and design.